Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir

Autor: Vannappagari, V., Thorne, C, Albano, Jd, Bowen, M, Cook, T, Garges, H, Ragone, L, Scheuerle, Ae, Tilson, H, Xue, Ym, Vielot N, Aebi-Popp, Burger, D, Colbers, A, Florida, M, Giaquinto, C, APPICC Collaborative Study
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Epidemiology
Abortion
Piperazines
Cohort Studies
chemistry.chemical_compound
Pharmacology (medical)
Registries
Pregnancy Complications
Infectious
Young adult
birth defect
dolutegravir
low birth weight
pregnancy
preterm
Obstetrics
Pregnancy Outcome
Abnormalities
Drug-Induced
Stillbirth
Infectious Diseases
Premature birth
Pregnancy Trimester
Second
Prenatal Exposure Delayed Effects
Cohort
Dolutegravir
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Premature Birth
Female
medicine.symptom
Heterocyclic Compounds
3-Ring
Cohort study
Adult
medicine.medical_specialty
Adolescent
Anti-HIV Agents
Pyridones
Young Adult
Oxazines
medicine
Humans
Pregnancy
business.industry
Infant
Newborn
Abortion
Induced
Infant
Low Birth Weight
medicine.disease
United States
CD4 Lymphocyte Count
Abortion
Spontaneous
Pregnancy Trimester
First
Low birth weight
chemistry
Fertilization
business
Zdroj: Journal of Acquired Immune Deficiency Syndromes (1999)
Popis: Supplemental Digital Content is Available in the Text.
Background: Birth outcome data with dolutegravir exposure during pregnancy, particularly in the first trimester, are needed. Setting: Data were prospectively collected from the Antiretroviral Pregnancy Registry and European Pregnancy and Paediatric HIV Cohort Collaboration. Methods: We reviewed 2 large, independent antiretroviral pregnancy registries to assess birth outcomes associated with maternal dolutegravir treatment during pregnancy. Results: Of 265 pregnancies reported to the Antiretroviral Pregnancy Registry, initial exposure to dolutegravir occurred at conception or first trimester in 173 pregnancies and during the second or third trimester in 92 pregnancies. There were 246 (92.8%) live births resulting in 255 neonates (9 twins), 6 (2.3%) induced abortions, 11 (4.2%) spontaneous abortions, and 2 (0.8%) stillbirths. Birth defects occurred in 7 (2.7%) of 255 live-born neonates, 5 (3.1%) of 162 (includes 6 twins) with conception/first-trimester exposure. Of 101 pregnancies reported to the European Pregnancy and Paediatric HIV Cohort Collaboration, outcomes were available for 84 pregnancies (16 continuing to term and 1 lost to follow-up). There were 81 live births (80 with known initial dolutegravir exposure at conception or first, second, and third trimesters in 42, 21, and 17 live births, respectively), 1 stillbirth (second-trimester exposure), 1 induced abortion (first-trimester exposure), and 1 spontaneous abortion (first-trimester exposure), respectively. Birth defects occurred in 4 live births (4.9%; 95% confidence interval: 1.4 to 12.2), 3 of 42 (7.1%) with exposure at conception or first trimester. Conclusions: Our findings are reassuring regarding dolutegravir treatment of HIV infection during pregnancy but remain inconclusive because of small sample sizes.
Databáze: OpenAIRE
Externí odkaz: